This conversation with Ian Rowe, Jörn Schattenberg and Roger Green continues to unpack the rich EASL Congress 2023 program by discussing abstracts and presentations of interest. The group dives deep into liver science with commentary around emerging developments in NAFLD/NASH therapeutics.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This final conversation explores hepatocellular ballooning and the power of AI-assisted pathological assessment.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This conversation considers how to lower screen fail rates and the prospect of establishing guidelines for the biopsy reading process.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. The group considers what exactly is moving the field rapidly forward. The focus of this conversation considers the future of AI-assisted digital pathology, NITs and screen fail rates.
Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. This conversation features Stephen’s take on the recent outcome of the FDA ADCOM meeting for obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH.
Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. The group dives deep into a range of topics including drugs with strong metabolic foundations, the state of histopathology, clinical trial design and screen fail rates, FDA ADCOM on obeticholic acid and much more.
Donna Cryer joins Jörn Schattenberg and Roger Green for a session which draws from raw reflections on the recent FDA Advisory Committee meeting and its outcome for obeticholic acid. The group remains focused on a critical message that looks down the path forward for the liver community and meeting patient needs. Stay tuned for more coverage as SurfingNASH continues to meet with other KOLs and stakeholders to discuss the event and its implications.
New guest Aleksander Krag joins Sven Francque and the surfers to discuss the upcoming EASL Congress in Vienna.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation From the Vault, the group discusses NITs and what will change between now and when this conference convenes next year.
